text:
translation of 59 words into 7 languages
This project was successfully completed by ihero for $64 NZD in 3 days.Get free quotes for a project like this
Completed by:
Skills Required
Project Budget$30 - $250 NZD
Completed In3 days
Total Bids60
Project Description
I would like to obtain a quote please from some translation. The attached word doc (WoW Home) shows a picture of the home page of a website I'm developing. I would like to translate the attached English text (59 words) in the excel file into the seven languages at the top of the excel file – so that I can make this same home page in the 7 additional languages.
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Hi all,
I have a 2005 X5 3.0i with non-xenon (halogen) headlights that use H7 bulbs. In the last several months, I began to notice that the headlights were flickering (pulsing) back-and-forth while driving; and thought that the light bulbs are going bad. I did not change the light bulbs immediately because of the long daylight hours in summer time in Minnesota (hence did not need to turn on the headlight much).
So the dark cold winter comes and I finally got around and buy a pair of H7 light bulbs and pop them in. The headlights still flicker...
Since my car is under CPO warranty, I did not want to mess it around any further. Took the car in and was hoping that dealer will take care of it.
Any two separate visits to two different dealers; including conversation with BMW NA, I was told that the heated seats in X5 will cause a surge in current draw and that is normal and no need to fix anything. They said there is a TSB for it and all the electrical system in my car tested ok.
However, the headlights were flickering even when the heated seats were not on - has anyone experience this at all?
Anyone out there experiencing similar problem? Thanks in advance.

subset: commoncrawl


text:
31 search results for Long Hot Summer
Watch: Keith Urban's got his toes in the sand for 'Long Hot Summer' video
Type: Post | Date: Wednesday, Aug 17, 2011Enjoy while there are still a few weeks left
'Review' premiere, 'Key & Peele' return lead Comedy Central summer plans
Type: Post | Date: Wednesday, May 20, 2015'Drunk History,' 'Another Period' and more get launch dates
Type: Event | Date: Wednesday, Oct 17, 2012Tessa and George return to our screens tonight.
Tech Support: 'Django,' 'Amazing Spider-Man' production designer J. Michael Riva has passed
Type: Post | Date: Thursday, Jun 7, 2012Veteran crewman was Oscar-nominated for 'The Color Purple'
We take you to the taping of Tim McGraw's upcoming TV special
Type: Post | Date: Tuesday, Apr 9, 2013Get the scoop weeks before you can see it on TV
Paul Newman and Joanne Woodward are the faces of this year's Cannes fest
Type: Post | Date: Friday, Mar 22, 2013The festival's official 2013 poster features a vintage shot of the loved-up couple
Bullet Points: Don't Cry for Me Apple Music
Type: Post | Date: Monday, Jun 22, 2015
Texas Chainsaw 3D
Type: Event | Date: Friday, Jan 4, 2013Leatherface is back for a 3D outing.
Song Of The Summer? Maroon 5's 'This Summer's Gonna Hurt Like A Motherf***er'
Type: Post | Date: Tuesday, May 26, 2015
Take this Waltz
Type: Event | Date: Friday, Jun 29, 2012Michelle Williams, Luke Kirby, and Seth Rogen star in this film about a women choosing between her husband and a new love.


text:
The Ambrosio Real Estate Team concentrates our efforts in assisting Sellers and Buyers with their Real Estate needs in Pinellas, Hillsborough, and Pasco with a special focus on Beach communities.
As an investor, we can help you find the right property for your needs, by working with a designated CCIM agent (Certified Commercial Investment Member).
Our professional team ensures that YOUR transaction goes as smoothly as possible by choosing the right people to assist in the different aspects; Real Estate is not a one person show, it takes dedication and knowledge to make sure of this.
Our agents invest their time & energy to get the most and the best results providing educated advice to our clients. If you need a dedicated professional to help you through the maze of buying and selling your home or your next investment property we'd love to help.
Please fill out the short form below, and one of The Ambrosio Team's world-class agents will contact you as soon as possible!


text:
Is Thomas Lennon gay or straight?Here you find the sexual orientation of Thomas Lennon.
Do you disagree? Please Inform us.
Do you like Thomas Lennon?
Thomas Lennon gaydarAccording to 19 visitors Thomas Lennon is 67% gay.
However, the average gay-rating on gay-or-straight.com is 69%, which means Thomas Lennon is quite straight in comparison to other celebrities on this website.
Please vote! How gay is Thomas Lennon?
not gay - - gay
not gay - - gay


text:
Website Video ( promotional )
This project received 17 bids from talented freelancers with an average bid price of $172 USD.Get free quotes for a project like this
Skills Required
Project Budget$30 USD
Total Bids17
Project Description
we are Webdesign Company looking for web video, something similar to this video
[url removed, login to view]
we need:
However the voice will be in Arabic language + another Version in English Language
its ONLY 60 sec !
IF you give good price, you will get more work , .:: we are looking for partners ::. ..
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Classical producer Alspaugh wins Grammy for Florentine/MSO recording
A project with ties to Milwaukee won a Grammy Award early Sunday night in the hours before the start of the 55th annual awards show in Los Angeles.
Blanton Alspaugh won the Grammy for classical producer of the year, in part for his work on the Florentine Opera and the Milwaukee Symphony Orchestra's recording of "Davis: Rio De Sangre," an original opera from Don Davis. »Read Full Article
Not summer? No problem for Chesney and fans
Forget what the calendar says. Summer officially came to Milwaukee Saturday with Kenny Chesney.
The 45-year-old country superstar brought his "No Shoes Nation" tour to about 41,000 people at a sold-out Miller Park Saturday night - but it was clear to the thousands of revelers that this was no mere concert. »Read Full Article(18)
Skylight Music Theatre delivers an intimate 'Porgy & Bess'
Powerful, emotional singing delivered a searing story of misery, heartbreak and hope in Friday's opening of the Skylight Music Theatre's "Porgy & Bess."
Directed by Bill Theisen - his last production as Skylight's artistic director - this "Porgy" relies on a chamber-ensemble cast and orchestra to tell a tale usually told with a huge chorus and full orchestra. »Read Full Article


text:
iHerb Customer Reviews
Savings of: $1.65 (15% off)
Best Lycopene
Posted by Reviewer2063209 on Sep 15, 2007
Simply the most potent, and best value for any Lycopene supplement I have ever seen. I do hope they never go out of business.
Lycopene Tablets
Posted by 5143716688954664704 on Sep 06, 2013
These tablets have worked fantastic for my husband who was always going to the toilet every hour. He now finds that he is a more normal visitor to the toilet. He is now on his second bottle and that is why we ordered 3 bottles to keep him stocked for longer. Thank you iherb for your fantastic service twice now and we will be back.
Strong and very affordable
Posted by naturellen on Jul 14, 2009
I used this product to safe-guard my skin from burning when vacationing in a beach resort. Worked very well.
Good Strength, Good Price
Posted by Reviewer2324732 on Dec 13, 2009
I honestly can't determine the effectiveness of this supplement, but I can only say that at 74 I still don't have prostate cancer. I've been taking the Lycopene for a number of years. Perhaps it has protected me.
great blood thinners
Posted by Reviewer1695400 on Jul 03, 2010
When I first saw how big they are it spooked me as Im the person who has to chew even the smallest bits of food, but I managed to swallow them ok. They are a very high dose. More than is needed, and I want them to act as a blood thinning aid for me. One daily and I startedbought them because I want to keep my blood thinner, which these do effectively, I found I was bruising very easily so guessing they work TOO well for me, but resolved this by taking less often, which makes them even cheaper for me. ;-) I do take other supplements, but I try and test them to see if they help or not as I cant afford to take ones that dont work. I can tell you theese DO work. You just might need one every other day though, or even three times a week only, if you use other supplements with blood thinning effects. Point is these really do work as blood thinning aid, about anything else, I dont know.
excellent for prostate problems
Posted by Reviewer1995730 on May 31, 2010
better than saw palmeto
Need a stronger strength
Posted by Reviewer1450575 on Aug 04, 2010
have to take too many of them to get the needed MG. Considering how small the Milligram is, it need to be MUCH smaller or oval shaped for easier swallowing. Get choked on such a large pill. Also, needs to be in an oil base for easier absorption.
Posted by Reviewer2679594 on Oct 29, 2008
Not as good as the Lycomato supplements
Therapeutic for prostate cancer
Posted by Reviewer1487212 on Apr 23, 2013
Studies have indicated that Lycopene may work therapeutic for prostate cancer and possibly other forms of cancer as well. I take it as a potent anti-oxidant and it works well for me.
Maximum strength at such a great value!
Posted by Reviewer1980672 on Jan 05, 2013
I buy this for my husband who is suffering from low sperm count and poor motility. We are preparing for IVF. This is the best lycopene I've found on the market.


text:
Chris Brown doesn't remember beating, is still in love with Rihanna
A couple details will be revealed about Chris Brown in his televised interview on CNN's "Larry King Live" on Wednesday. For one, he doesn't remember beating up his then-girlfriend Rihanna and, two, he's still in love with her.
As the clip below reveals, Brown has little to say beyond "wow" when it comes to the police reports and the endless reiterations of his violent incident. "I just don't know what to think. It's just like, wow," Brown said.
When asked by King if he remembers hitting her, Brown just shakes his head. "It's crazy to me. I'm like, wow."
As for seeing the now-infamous photo of Rihanna's bruised and cut face, Brown sayshe's haunted. "When I look at it now, it's just like, wow, like, I can't believe that that actually happened."
Brown, dressed in a light blue sweater and matching blue bowtie, is flanked by his lawyer and his mother, the latter of which was shocked when Brown told her what had happened. She said he had never been violent before.
But that's not what Brown's probation report said. He and Rihanna had been involved in two other domestic violence disputes. Once, he shoved her into a wall after she slapped him, and once he broke the windows to a car after she and him had been in a fight inside it.
This marks the first time Brown has been interviewed on TV since the assault and subsequent court dates. He was sentenced to five years probation and six months of community service.
The assault in February occured right before both singers were scheduled to appear at the Grammy Awards, after a fight erupted when Rihanna found a text message on Brown's phone from a former lover.
In a YouTube post that looks like it was shot in, say, a publicist's office, Brown apologized for the "incident" and "what happened" in July. He declined to mentioned "what happened" is beating his girlfriend up.


text:
Government Investigations - How to Respond to a Search Warrant: 10 Practical Steps
Amended Rules Five Months Later: Early Trends in Case Law and What It Means
Episode 11: Better Know a Judge: Vice Chancellor Joseph R. Slights, III of the Delaware Court of Chancery
CorpCast Episode 10: eDiscovery Review
CorpCast Episode 9: 2015 Year in Review
The Challenge of Returning Forfeited Assets to Corrupt Countries
Morgan Lewis Partner Suet-Fern Lee on the Rule of Law
Litigation Hold Letters
December 2015 Changes to the Federal Rules of Civil Procedure: A BakerHostetler Q&A
CorpCast Episode 8: The Controlling Stockholder
CorpCast Episode 7: Better Know a Judge: the Honorable Mary M. Johnston of the Delaware Superior Court
CorpCast Episode 6: A Brief Introduction to the Delaware Rapid Arbitration Act
FCPA Compliance and Ethics Report-Episode 168-Dan Cogdell on criminal procedure issues in defending an individual prosecuted criminally under the FCPA
CorpCast Episode 5: The eDiscovery Big Picture
Halliburton: Good for the Plaintiffs' Bar?
Reservation of Rights and the Insurer
CorpCast Episode 4: Better Know a Judge: Vice Chancellor J. Travis Laster of the Delaware Court of Chancery
CorpCast Episode 3: Preview of Business Divorce CLE at 2015 ABA Business Law Section Spring Meeting
CorpCast Episode 2: Advancement 101
CorpCast Episode 1: Sections, 204, 205 and In re Numoda
This is one of two recent Court of Chancery decisions explaining that the Corwin case really does mean that there is an "irrebuttable business judgment rule" that bars challenges to a merger approved by a majority of the...more
It is well-settled under Delaware law that in a merger a stockholder loses standing to assert a purely derivative claim. That claim passes instead to the acquiring company. As an asset of a Delaware company, derivative claims...more
This decision applies the Corwin doctrine to dismiss a suit attacking a merger that received stockholder approval. It explains that approval by a fully-informed, uncoerced majority of disinterested and independent...more
In combination with the Delaware Court of Chancery's decision in In re Trulia, Inc. Stockholder Litigation, 129 A.3d 884 (Del. Ch. 2016), Judge Posner's blistering opinion In re Walgreen Company Stockholder Litigation, 2016...more
Among the most-discussed issues in corporate law today is whether appraisal actions should be curtailed. Triggered by above-merger price awards after deals were shopped in the market, the argument is that the appraisal...more
In this memorandum opinion, the Court of Chancery dismissed claims for breach of fiduciary duty under Chancery Rule 12(b)(6), holding that an irrebuttable business judgment rule standard applies to a merger effected under...more
Last week, in an opinion authored by Judge Richard Posner, the U.S. Court of Appeals for the Seventh Circuit rejected a proposed class-action settlement arising from Walgreen Co.'s acquisition of the Swiss-based pharmacy...more
Vice Chancellor Glasscock has held that a merger designed to eliminate derivative claims against a majority of directors justified the application of the entire fairness standard of review in a direct challenge to the merger....more
The Court of Chancery's highly-publicized decision in In re Trulia, Inc. Stockholders Litigation, 129 A.3d 884 (Del. Ch. 2016) (Bouchard, C.) (discussed here) took aim at the problem of disclosure-only settlements and...more
This is an excellent explanation of the corporate opportunity doctrine's four elements, under which directors may be liable for taking a business opportunity that: (1) the corporation is financially able to take for itself;...more
Foundation Surgery Affiliate of Southwest Houston, LLC ("Southwest"), the owner of a surgical and imaging facility in Houston, entered into a purchase and sale agreement in 2008 with Rainier Capital Acquisitions, LP, which...more
In Tonn v Sears Canada Inc.1 the British Columbia Supreme Court rejected a plaintiff's attempt to certify a class action for wrongful dismissal under the Class Proceedings Act2 ("CPA"). However, this was not the end of the...more
The Delaware Court of Chancery recently held that where a majority of a corporation's fully informed, disinterested, and un-coerced stockholders tender their shares as part of a two-step merger, that has the same "cleansing"...more
In In re Volcano Corporation Stockholder Litigation, the Delaware Court of Chancery recently held that majority stockholder approval of a merger under Delaware General Corporation Law Section 251(h) by accepting a tender...more
[The Court's] determination reflects the healthcare world as it is, and not as the FTC wishes it to be. We find it no small irony that the same federal government under which the FTC operates has created a climate that...more
In what might be one of the most important decisions this year, the Court held that the tender of their shares by a majority of the stockholders invokes an "irrebuttable" presumption that the business judgment rule applies...more
Last month, the New York Court of Appeals issued a decision rejecting the attempted expansion of the common interest exception to the attorney-client privilege to include communications that did not involve pending or...more
In what will undoubtedly be seen by all interested parties as a significant setback in the Federal Trade Commission's active opposition to potentially anticompetitive healthcare collaborations, the FTC voted unanimously on...more
On June 16, 2016, Delaware Governor Jack Markell signed into law House Bill No. 371, which makes a number of noteworthy changes to the Delaware General Corporation Law ("DGCL"). The most significant 2016 amendments to the...more
On January 22, 2016, Chancellor Bouchard rejected a proposed disclosure-only settlement inIn re Trulia, Inc. Stockholder Litigation, 129 A.3d 884 (Del. Ch. 2016), marking the culmination of what has been a seismic shift over...more
Delaware law has long made clear that the price established for a company in a market transaction, while a relevant factor, does not necessarily equate to the fair value that shareholder claimants are entitled to receive in...more
Vice Chancellor Laster of the Delaware Chancery Court recently issued an important opinion in In Re: Appraisal of Dell Inc.C.A. No. 9322-VCL (May 31, 2016), holding that merger consideration offered to Dell, Inc's common...more
The Delaware Court of Chancery (the "Court") recently ruled that the fair value of Dell Inc. shares at the time of the 2013 US$24.9 billion buyout of Dell Inc. by CEO Michael Dell and Silver Lake Partners was US$17.62 per...more
Court of Chancery Applies Entire Fairness Standard to Commercial Arrangement with Controlling Stockholder -
In a recent opinion, Vice Chancellor Laster of the Delaware Court of Chancery held...more
In this opinion, the Court of Chancery held that, through the "Byzantine and path-dependent system by which stockholders voted on a proposed merger," fourteen mutual funds sponsored by T. Rowe Price & Associates, Inc. ("T....more
Find a Civil Procedure Author »
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.
JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.
The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.
JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.
If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.
Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.
JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.
If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at email@example.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.
Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.
In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.
This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.
We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.
If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: firstname.lastname@example.com.
Already signed up? Log in here
Back to Top
Explore 2016 Readers' Choice Awards
Copyright ©


text:
Monster kills grant +29 experience.
Monster kills grant +15 experience.
Monster kills grant +13 experience.
Monster kills grant +49 experience.
Monster kills grant +18 experience.
Monster kills grant +43 experience.
Monster kills grant +45 experience.
Monster kills grant +33 experience.
Monster kills grant +12 experience.
Monster kills grant +17 experience.
This feature lists your most prevalent gear bonuses. You may select a bonus to see which items provide that bonus.
Strength: 1086
Primary attribute for Barbarians and Crusaders.
Increases all damage for Barbarians and Crusaders by 1086.00%.
Increases Armor by 1086.
Dexterity: 57
Primary attribute for Demon Hunters and Monks.
Increases all damage for Demon Hunters and Monks by 57.00%.
Increases Armor by 5.70%.
Intelligence: 57
Primary attribute for Witch Doctors and Wizards.
Increases all damage for Witch Doctors and Wizards by 57.00%.
Increases resistances by 5.7.
Vitality: 728
Increases Life, allowing more damage to be taken before dying.
Each point of Vitality increases Life by 25.
Armor: 1847
Reduces all damage from enemies of the same level as you by 0.00%.
Damage: 1695.04
The amount of damage per second you can deal.
Damage is based on your weapons, attributes, attack speed, Critical Hit Chance,
Critical Hit Damage, passive skills, and dual-wielding attack speed increase.
Toughness: 33430
The total amount of raw damage you can take.
Toughness is based on your maximum Life, armor, dodge chance,
average resistances, and missile, melee, and elite damage reduction.
Recovery: 103
The amount of Toughness you can recover every second in combat.
Recovery is based on your Toughness, Life per Hit, Life per Second, Life per Kill,
Life per Fury/Spirit/Wrath Spent, Life Steal, and Health Globe Healing Bonus.
Maximum Life: 19086
If you lose all your Life, you die.
Life can be increased by skills, items, and Vitality.
Fury 100/100
Generated when the Barbarian uses Fury generating skills
or takes damage. Used for more powerful Barbarian attacks.
Last updated on 18 Oct 2015 21:56 BST


text:
This demostration shows LCNB On-Line's functionality, ease of navigation and all the great features available.If you would like to enroll** in LCNB On-Line, please go to our home page www.lcnb.com and click on Enroll Now or you may also stop by any of our branches to complete an EZ Enrollment Form and we will get you started banking anytime, anywhere by just a Point, Click and Bank!!
**Online enrollment is for personal accounts only. If you are a business or association, please stop into your local branch to enroll.


text:
orangecookie image and sound Plus
User Stats
Profile Images
User Bio
as animator ☂ tiny objects and brightly colored things in motion ☁
● multimedia work ● stopmotion animation, porcelain objects, video, and sound art ●
✮ Slowly-moving changes of sound combined with packets of visual information using
modular synthesizers/electronics, piano, harp, and field recordings. Stopmotion video, liquid light visuals, painting, and porcelain ✮
as vj orangecookie ☼ live artifact-saturated processing with original stopmotion images and original footage☀
★ and in the duo, twin stars with michael t. bullock ☆ Twin Stars ✫
❀musician❀analog synth❀harp❀guitar❀kybd❀
citizens for confetti
rise set twilight
Twilight of the Century
External Links
- shadowselves (collaborations) - With Michael T. Bullock https://vimeo.com/fielderblank
- orangecookie (visual and sound) - All visual content, including Aubry Arts (porcelain), video, and painting. Music projects.


text:
See by Chloé Frayed Denim Skirt
'Stan Smith' Sneaker (Women)
Perforated stripes detail the sides of an iconic tennis shoe updated in a breezy mesh upper with a reflective overlay and finished with a contrasting logo overlay at the heel. Lace-up style. Leather or leather and synthetic upper/synthetic and textile or textile lining/rubber sole. By adidas; imported. BP. Shoes. Helpful ... Learn More
Women's Ag 'The Sloan Vintage' Distressed Straight Leg
Fine Japanese denim woven with a bit of stretch adds just the right amount of weight to vintage-inspired jeans finished with threadbare patches and bold sanded detailing for a lived-in look. Cuffed hems and a straight-leg fit further the casual-cool appeal of these versatile jeans. Color(s): 20y carved stone. Brand: ... Learn More
Women's Vans 'Sk8-Hi' Moc Sneaker, Size 9 M
Fringe trim provides an on-trend update to a standout high-top sneaker shaped from lush suede and set on a sturdy rubber sole. Color(s): black suede, blanc de blanc suede, burgundy suede, infinity/ blue suede, ivy green suede, monk/ brown suede. Brand: VANS. Style Name:Vans 'sk8-Hi' Moc Sneaker (Women). Style Number: 1172734. ... Learn More
Women's New Balance '580' Sneaker, Size 9.5 B
Paneled in rich suede, a New Balance original is updated with color-pop accents and a mixed-media finish. The REVlite midsole is exceptionally flexible and lightweight, while a durable gum-rubber sole adds a classic touch. Color(s): black, envy, green/ lead, grey, steel, supernova red. Brand: NEW BALANCE. Style Name:New Balance '580' ... Learn More
Women's Ag 'Stilt Cigarette' Skinny Jeans, Size 32
An inky black wash helps streamline the silhouette of these figure-whittling jeans topped with a chic low-rise waist. The best part: These skinnies are cut from a luxe blend of fabrics that will contour your curves and maintain incredible shape retention. Color(s): super black. Brand: AG. Style Name:Ag 'stilt Cigarette' ... Learn More
Women's Marchesa Beaded Lace Off The Shoulder Peplum
Corded embroidery, glossy beads and delicate floral appliqués create opulent texture for a lace-trimmed evening blouse designed to focus attention on lovely shoulders and a slender waist. A flounced peplum hem and scalloped edges complete the darkly romantic look. Color(s): black. Brand: MARCHESA. Style Name:Marchesa Beaded Lace Off The Shoulder ... Learn More
Women's Vans 'Sk8-Hi' Slim Zip Sneaker, Size 8
A channel-quilted padded collar tops a favorite Vans high-top sneaker styled in herringbone tweed and finished with a back zipper for on-trend appeal. Color(s): black embossed, cool grey scotchgard, leather wind chime, leather zephyr blue, obsidian scotchgard. Brand: VANS. Style Name:Vans 'sk8-Hi' Slim Zip Sneaker (Women). Style Number: 1172551. Available ... Learn More
Women's Brooks 'Vanguard' Sneaker
Revisit the thrill of the '70s running boom with the much-anticipated re-release of the iconic 1976 Brooks Vanguard, styled with the signature clean lines of the chevron and T-toe. Color(s): adriatic blue/ cloud cream, anthracite grey/ gold, charcoal, cloud grey/ honeydew/ white, coral reef/ fuchsia purple, deep grey, deep lake/ ... Learn More


text:
|2015-11-04 03:47:43 by Alistair G. Crooks | Files touched by this commit (758)
Log message: Add SHA512 digests for distfiles for www category Problems found locating distfiles: Package haskell-cgi: missing distfile haskell-cgi-20001206.tar.gz Package nginx: missing distfile array-var-nginx-module-0.04.tar.gz Package nginx: missing distfile encrypted-session-nginx-module-0.04.tar.gz Package nginx: missing distfile headers-more-nginx-module-0.261.tar.gz Package nginx: missing distfile nginx_http_push_module-0.692.tar.gz Package nginx: missing distfile set-misc-nginx-module-0.29.tar.gz Package nginx-devel: missing distfile echo-nginx-module-0.58.tar.gz Package nginx-devel: missing distfile form-input-nginx-module-0.11.tar.gz Package nginx-devel: missing distfile lua-nginx-module-0.9.16.tar.gz Package nginx-devel: missing distfile nginx_http_push_module-0.692.tar.gz Package nginx-devel: missing distfile set-misc-nginx-module-0.29.tar.gz Package php-owncloud: missing distfile owncloud-8.2.0.tar.bz2 Otherwise, existing SHA1 digests verified and found to be the same on the machine holding the existing distfiles (morden). All existing SHA1 digests retained for now as an audit trail.
|2015-10-04 17:40:20 by Takahiro Kambe | Files touched by this commit (2) |
Log message: Update thin to 1.6.4. == 1.6.4 Gob Bluth * Increase REQUEST_PATH to 2048 symbols [X2rdas] * Fix warning in logger [tenderlove] * Add :timeout option for Rack::Server.new [sugitak] * When restarting, exit on a next tick so we can send response back to a client \ [rsamoilov] * Check for empty PID files [z1dane] * Update Event Machine version to 1.0.4, Ruby 2.2.0 fix [freemanoid]
|2015-03-08 17:10:37 by Takahiro Kambe | Files touched by this commit (1)
Log message: Depends on ruby-rack15 instead of ruby-rack to solve indirect dependency problem. Noted by joerg@ via private e-mail.
|2015-03-08 16:17:22 by Takahiro Kambe | Files touched by this commit (58) |
Log message: Add ${GEM_EXTSDIR}/gem.build_complete for new rubygems and updated ruby.
|2015-03-01 16:41:36 by Takahiro Kambe | Files touched by this commit (4) |
Log message: Update thin to 1.6.3. pkgsrc change: Add pkg_alternatives support. == 1.6.3 Protein Powder * Add HTTP 422 status code [rajcybage] * Add warning about EM reactor still running when stopping. * Remove version number from "Server" HTTP header. [benbasson] * Adding `--ssl-disable-verify` to allow disabling of client cert requests when \ SSL enabled [brucek] * Ensure Tempfiles created by a large request are closed and deleted. [Tonkpils]
|2014-03-14 20:31:19 by Takahiro Kambe | Files touched by this commit (3) |
Log message: Update thin to 1.6.2. == 1.6.2 Doc Brown * No longer replace response's body on HEAD request. Ensuring body.close will \ be called. * Remove `---ssl-verify` option as EventMachine doesn't verify the certificate. * Fix env['rack.peer_cert'] to return SSL certifcate. == 1.6.1 Death Proof * Regression: Default logger to STDOUT when using outside of CLI. * Regression: Downgrade Rack required version back to 1.0 to work w/ prior \ Rails versions. == 1.6.0 Greek Yogurt * Accept absolute URL in request line, eg.: 'GET http://site.com/he/lo HTTP/1.1'. * HEAD request no longer return a body in the response. * No longer stop EventMachine's reactor loop unless it was started by Thin. * Make request env keys upcasing locale-agnostic. * Use Ruby's `Logger` for logging. [Akshay Moghe]. The logger can now be set using `Thin::Logging.logger=`. Tracing of request is handled by a second logger, `Thin::Logging.trace_logger=`. * Add --threadpool-size option to configure EM's thread pool size (default: 20). * Pipelining is no longer supported.
|2014-03-13 12:08:54 by Jonathan Perkin | Files touched by this commit (67)
Log message: Set USE_GCC_RUNTIME=yes for packages which build shared libraries but do not use libtool to do so. This is required to correctly depend upon a gcc runtime package (e.g. gcc47-libs) when using USE_PKGSRC_GCC_RUNTIME.
|2013-09-15 19:59:44 by Takahiro Kambe | Files touched by this commit (2) |
Log message: Update thin to 1.5.1. == 1.5.1 Straight Razor * Fix issue when running as another user/group without a PID file. * Allow overriding Connection & Server response headers. * Update vlad example [Mathieu Lemoine] * Keep connections in a Hash to speedup deletion [slivu] * Force kill using already known pid. Prevents "thin stop" from leaving a process that removed its pid file, but is still running (e.g. hung on some at_exit callback) [Michal Kwiatkowski]


text:
PHOTO: Perry Riley Jr. Signs with Redskins
The Washington Redskins have reached an agreement to keep their inside linebacker. They tweeted a photo of Perry Riley Jr. signing his contract today.
IMAGE: @PR56 LB Perry Riley Jr. signing his new contract. #HTTR pic.twitter.com/BmwEqJncQm
? Washington Redskins (@Redskins) March 11, 2014
Follow Perry on Twitter for more updates!


text:
webFEAT complete provides quality, dependable and affordable hosting packages. Our hosting fees include web based email access, as well as POP3 and IMAP email accounts. Our email service also include filtering for protection against viruses and SPAM. When needed, FTP access can be provided. Contact webFEAT Complete today for more detailed information.
webFEAT Complete is an EXPERT in network administration and maintenance and domain name transfers. Managing hosting, doing it through a large company with less personal support and service and transferring domains on your own can be difficult and time consuming. Contact Us today for quality assistance that is on call for your business 24/7.
Phone : (513) 272-3432


text:
Visit us
Trifecta serves dinner seven days a week.
Monday: 5 pm to 9 pm
Tuesday-Thursday: 5 pm to 10 pm
Friday & Saturday: 4 pm to 10:30 pm
Sunday: 4 pm to 9 pm
8 am to 1 pm daily (pastries and bread)
4 pm to close, daily (bread only)
Happy Hour:
Monday-Thursday: 5 pm to 6 pm
Friday & Sunday: 4 pm to 6 pm
Saturday: 4 pm to 5 pm
Owner Ken Forkish opened Trifecta after establishing two of Portland's most beloved locales, Ken's Artisan Bakery and Ken's Artisan Pizza. The lengthy growing seasons in the Pacific Northwest largely dictate Executive Chef Rich Meyer's menu and nightly specials. Colin Carroll heads Trifecta's beverage program, which features balanced, classic cocktails with house made ingredients.


text:
Philips 24" LED 720p HDTVItem#: YYI1-RC2424 | Model#: 24PFL4508/F7
Currently Out Of Stock!
You May Consider This Alternative
24IN CLASS LCD LED TV 1366X768P Product Details
- Digital Crystal Clear is a package of picture innovations that digitally adjusts and optimizes picture quality to optimal contrast, color and sharpness levels
- PC input allows use of TV as a PC monitor
- USB connection enables viewing of jpeg photos and movies
- Connections: 3-HDMI, USB, PC, component, composite, RCA L/R stereo in, 3.5mm stereo out and digital coaxial audio out
- 1366 x 768 pixel resolution
- 230 cd/m2 brightness
- 8.5 ms response time
- 7500:1 contrast ratio
- Dolby® Digital and SRS TruSurround XT® sound features
- Panel: 22 3/4" W x 14 3/8" H x 2 7/16" D
- Energy Star® rated
Related ItemsPrevious
Manufactured by: Philips Consumer Electronics
Warranty provided by: Philips Consumer Electronics
UPC No: 609585230644
Mfg Part No: 24PFL4508/F7
Box Size:
( Length:0, Width:0, Depth:0)
Shipping Weight: 10.0000 pound(s)
Click here for full warranty and support information
- Philips Consumer Electronics logos are registered trademarks of Philips Consumer Electronics. All others trademarks and copyrights mentioned herein are the property of their respective owners.


text:
Left Masthead
September 25, 2016
Lavrov Says He Agrees With Kerry That Ukraine Should Uphold Feb. 21 Accord
Posted on Mar 5, 2014
Lavrov says agreed with Kerry that Ukraine should uphold February 21 accord (via AFP)
Russian Foreign Minister Sergei Lavrov said Wednesday that he and US Secretary of State John Kerry agreed that Ukraine should uphold a deal signed two weeks ago between now-ousted president Viktor Yanukovich and the opposition. "We agreed that it is…
Square, Site wide
New and Improved Comments
If you have trouble leaving a comment, review this help page. Still having problems? Let us know. If you find yourself moderated, take a moment to review our comment policy.
Join the conversation
Load Comments


text:
HD Argonian Warpaints
Skyrim » Models and Textures
Skyrim » Models and Textures
Added: 25/06/2013 - 09:04PM
Updated: 02/04/2016 - 10:46PM
Last updated at 22:46, 2 Apr 2016 Uploaded at 21:04, 25 Jun 2013
♥ ♥ ♥ Take a look at my website for more cool stuff! ♥ ♥ ♥
A high quality 2048x2048 version of the original Argonian Warpaints by kibblesticks
Additional HD Argonian Warpaints
Manual installation:
Unpack the zip into your Skyrim data folder.
Download and install Skyrim Script Extender (SKSE) (1.6.6 or later)
Check the Data folder and create the SKSE folder if necessary
Check the SKSE folder and create the SKSE.ini file if necessary
Open SKSE.ini
Add the following entry to the .ini file if necessary
Manual Uninstallation:
Delete the following files:
Delete the following folders:
If you use this mod on your argonians character feel free to upload a picture!
I'd love to see all the awesome argonians of skyrim. :)


text:
Assessing the 1988-2000 employment growth projections
May 29, 2003
How accurate were the 1988-2000 employment outlooks that appeared in the 1990-91 Occupational Outlook Handbook?
The 1990-91 Handbook categorized projected occupational employment change between 1988 and 2000 with the following descriptors:
|Growth descriptor
|Projected employment change
|Much faster than average
|increase 31 percent or more
|Faster than average
|increase 20 to 30 percent
|About as fast as average
|increase 11 to 19 percent
|More slowly than average
|increase 4 to 10 percent
|Little or no change
|increase or decrease 3 percent or less
|decrease 4 percent or more
Of 338 occupations, 87 had actual employment changes that matched the projected descriptor; another 100 had employment changes that were a single category higher or lower. There were 74 occupations with employment changes that were 2 categories away from the projection; 49 that were 3 categories away, and 16 that were 4 away. There were 12 occupations that had employment changes 5 categories away—occupations projected to grow much faster than average that actually declined, or vice-versa.
These data are from the BLS Employment Projections program, which produces the Occupational Outlook Handbook. More information on the accuracy of employment projections can be found in "The 1988-2000 Employment Projections: How accurate were they?" by Andrew Alpert and Jill Auyer, Occupational Outlook Quarterly, Spring 2003.
Related Articles:
Bureau of Labor Statistics, U.S. Department of Labor, The Economics Daily, Assessing the 1988-2000 employment growth projections on the Internet at http://www.bls.gov/opub/ted/2003/may/wk4/art03.htm (visited September 29, 2016).
Recent editions of Spotlight on Statistics
A look at healthcare spending, employment, pay, benefits, and prices
As one of the largest U.S. industries, healthcare is steadily growing to meet the needs of an increasing population with an increasing life expectancy. This Spotlight looks at how much people spend on healthcare, current and projected employment in the industry, employer-provided healthcare benefits, healthcare prices, and pay for workers in healthcare occupations.
Employment and Wages in Healthcare Occupations
Healthcare occupations are a significant percentage of U.S. employment. Some of the largest and highest paying occupations are in healthcare. This Spotlight examines employment and wages for healthcare occupations.
Fifty years of looking at changes in peoples lives
Longitudinal surveys help us understand long-term changes, such as how events that happened when a person was in high school affect labor market success as an adult.


text:
"Anytime there is a red flag warning in our area, it brings up the level of intensity of what we're doing, said Asotin County Fire Chief Noel Hardin.
Hardin has his crews on high alert and ready to take on anything over the next few days should all the wrong elements come together when lightening strikes.
"We're tracking storms that have been coming through our area right now," said Hardin. "With technology we can actually see where the lightening strikes, and that sort of thing, and so we'll put patrols out in those areas."
At the top of Lewiston hill, it was extremely windy Monday. There are low levels of humidity in the Valley and lots of dry areas, so the possibility of lightning strikes put the area at a red flag warning.
"The storms that have been coming through the area the last couple of days, there has not been a lot of moisture so our level of intensity is a lot higher," said Hardin. "Because of that we're going to be watching a lot closer if there is no moisture with it."
Due to the conditions, the potential for a fire to escalate quickly has local Valley agencies all working together to help each other out.
"We have a wild land red flag task force, that we set up with our mutual aid partners, that if a fire does start we will automatically send assistance right away," said Lewiston Fire Chief Garry DeJong.
DeJong said residents in the Valley can assist the fire departments by staying alert.
"The best thing they can do is continue to be safe with the practices that they do," said DeJong. "If they have a garden hose or a fire-extinguisher, just something nearby so they can help control that should something start."
Hardin also said they need everyone's eyes watching out for any sparks.
"Sometimes people are hesitant to call 911, but we'd be real happy if they let us know if they see something," said Hardin.
Hardin advises that maintaining your property and making sure there is no dry grass or weeds up against your building can do a lot to protect your home.


text:
• Age-related Macular Degeneration (AMD)
• Diabetes
• Macular Telangiectasia Type 2 (MacTel)
• Retinal Degenerations
• Retinitis Pigmentosa
• Retinoblastoma
• Uvelitis and Ocular Immunology
NTMT503 A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea® for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
PI: Jiong Yan, M.D.
Coordinator: Donna Leef, MMSc, COMT
Status: starting enrollment
General Summary:
This research study is for an investigational new treatment; a treatment that has not yet been approved for marketing by regulatory authorities. This investigational treatment is called the NT-503-3 intraocular encapsulated cell technology (ECT) implant. This study will assess whether this experimental implant can be used to treat people with reoccurring wet AMD. The goal of this treatment is to ultimately avoid the need for frequent injections into the eye.
Clinical Summary:
The NT-503-3 ECT implant contains tiny capsules (smaller than a grain of rice) of living cells that continuously release a soluble VEGF receptor for an extended period. The ECT implant is surgically implanted into the eye with a minor procedure under local anesthesia.
The goal of this treatment is to ultimately avoid the need for frequent injections into the eye. The study will compare the safety and efficacy of the NT-503-3 ECT implanted in the eye to the Eylea® injection treatment every 8 weeks that is already available for wet AMD.
Inclusion Criteria:
•Male or female, age 50 years or older
•Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD, as determined by the reading center,in at least 1 eye, the study eye at the screening visit.
•Must have received at least 3 intravitreal anti-VEGF injections (Avastin®, Lucentis® or Eylea®) in the study eye with at least 1 injection of Avastin® or Lucentis® or Eylea® in the previous 4 months
•Vision 20/40 to 20/320 in the study eye and at least 20/200 in the non-study eye
Exclusion Criteria:
•Vision worse than 20/320
•never received any anti-VEGF injections
•Subretinal hemorrhage: More than 50% of total lesion size in the study eye, as determined by the central reading center.
•Scar and/or, fibrosis: More than 25% of the total lesion size in the study eye; scar, fibrosis or atrophy (includingRPE) involving the center of the fovea as determined by the reading center.
•Inadequately responsive to the most recent anti-VEGF therapy
Contact: Donna Leef, MMSc, COMT (404) 778-4134 firstname.lastname@example.com
Posted: 05-18-2015
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
PI: Timothy W. Olsen, MD
Coordinator: Deborah Gibbs
Status: Recruiting
General Summary: Geographic atrophy (GA) is a form of dry age-related macular degeneration (AMD). GA causes progressive damage to the macula, the central region of the retina (inside the eye), which is involved in seeing the fine details associated with reading, driving, and recognizing faces.
In the advanced stage of the disease, GA results in severe central vision loss, which impairs performance of many activities of daily living. The cause of AMD is not well understood. However, recent scientific studies have found that people with specific inherited (genetic) characteristics have an increased risk of AMD.
Other scientific studies also suggest that an increased activation of a specific part of your immune system called the "alternative complement pathway" may be involved in the disease. Currently, there is no approved treatment for GA.
Lampalizumab, the study drug, is designed to slow down the activation of the alternative complement pathway and is given by injection into the eye. The trial visit schedule is once a month for a two-year commitment. Injections or shams will be given monthly. All study visits are covered by the sponsor.
Clinical Summary: In summary, the Phase II results from Study CFD4870g provided evidence that inhibition of the ACP with lampalizumab may slow the progression of GA and that lampalizumab administered as 10-mg intravitreal injections monthly over 18 months demonstrated an acceptable safety and tolerability profile in patients with GA secondary to AMD.
In addition, the exploratory genetic analyses suggest that there may be a biomarker-defined population (CFI profile biomarker-positive) that may have more rapid progression of disease and potentially derive greater efficacy benefit from lampalizumab than a group that is negative for the biomarker (CFI profile biomarker-negative).
On the basis of the findings from the Phase I and II studies, the Phase III study aims to further evaluate the efficacy and safety of lampalizumab as well as the potential for the CFI profile biomarker to identify patients who may have more rapid progression of disease and may derive greater benefit from lampalizumab treatment.
Inclusion Criteria:
1. ≥50 yrs. of age
2. VA equal or better than 20/100 SE
3. GA 2°to AMD ø CNV new or prior OU
4. Cataract surgery if ≥ 3 month prior
5. GA lesion size ≥1DA but ≤7DA
6. GA lesion must reside completely within the FAF imaging field OU
7. Presence of Hyper FAF of either banded or diffuse patterns adjacent to the area of GA SE
8. Valid CFI profile marker (test sent on scr date)
9. Relative clear ocular media, pupil dilation and fixation OU
Exclusion Criteria:
1. prior tx for AMD OU
2. prior tx for CNV, DME, RVO, PDR, CSR, RD, MH Stage 3 / 4 OU
3. PK (SE), Lasik, recurring eye infections or inflammation disease OU
4. RPE tear that involves the macula OU
5. eye problems (Cat, DR) that would need intervention to treat or prevent VA loss resulting from that disease or left untreated could ≥ 2 lines of VA loss during study
6. BP ≥180/110 sitting
7. Metabolic dysf, active systemic infection, malignancy, Ø Hx of Uveitis OU
8. predisposition or Hx of chronic immunosuppression/splenectomy
9. glaucoma-uncontrolled or filtering surgery OU
Contact: Deborah Gibbs, COMT, CCRC, CCRP 404-778-5815
Posted: 03-11-2014
A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovistatm (anti pdgf-b pegylated Aptamer) administered in combination with lucentis® compared to lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration
PI: Ghazala D. O'Keefe, MD
Coordinator: Deborah Gibbs, COMT, CCRC, CCRP
Status: Closed to enrollment.
Summary: FovistaTM (also known under the code name of E10030) is an investigational drug being studied by Ophthotech Corp. and is for the treatment of age-related macular degeneration (AMD). An investigational drug is one which has not been approved by the U.S. Food and Drug Administration (FDA). FovistaTM (E10030) is given by injection into the vitreous, which is the clear, jelly-like substance that fills the middle of the eye.
Lucentis® (ranibizumab) is an approved drug for AMD, and is also given by injection into the vitreous. Lucentis® is an "anti-VEGF" agent; that is, it blocks "vascular endothelial growth factor", which plays a major role in the onset of wet AMD.
FovistaTM works differently than the "anti-VEGF" agent Lucentis®. FovistaTM is an "anti-PDGF" agent; that is, it blocks a different growth factor— "platelet-derived growth factor"—that also plays a role in wet AMD. In two previous studies, FovistaTM combined with Lucentis® was well tolerated. Although these studies revealed that the combination of Lucentis® and FovistaTM may have the potential to stop or reverse the growth of abnormal blood vessels in the eye and can possibly improve vision, you may or may not benefit from receiving FovistaTM in addition to Lucentis®, by participating in this study.
The purpose of this study is to further evaluate the effects of Fovista™ in patients with wet AMD, and how Fovista™ is absorbed into the body, when administered in combination with Lucentis®.
This study will involve approximately 622 men and women ages 50 years or older world-wide. We expect 15-20 here at Emory. Your participation in this study will last approximately 24 months.
Inclusion Criteria
• BCC Study Eye 20/63-20/200
• Wet AMD
• Total area <5 Disc areas 50% active CNV (active leakage and sub/intraretinal fluid on OCT
• OCT results of sub/intraretinal or sub-RPE fluids/o SR thick/reflectivity consistent with active CNV
• IOP 21 or less
• >50 yo
• Ability to comply with 24-26 visits, etc.
Exclusion Criteria
FPrior intravitreal tx in study eye
25% if the total lesion size consisting of subretinal H+
>50% of total lesion size SRH
Presence of significant Serous PED (such as large PED that constitute greater than 50% if the total lesion)
Pigment epithelial tears or rips
Intraocular inflammation
Sig cataracts requiring sx in 12 months
Presence of Pathologic myopia, histo, angioid streaks, choroidal rupture, multifocal choroiditis
Hx of RRD, PPV, Trab, Glaucoma drainage device, PK
Radiation in the region of the study eye.
DM or A1c of >6.5
Metabolic dysfunction
Labs results showing underline problems
HX or evidence of Severe Cardiac disease
Unstable angina
Acute coronary syndrome
Coronary Revascularization w/in 6 mo
Ventricular tachyarrhythmia's ongoing tx
Stroke w/in 12 months of trial
Major surgery w/in 1 month
Any tx w/investigation agent w/in 60 days for any condition
Allergy to FA dye, Lucentis, Fovista
Contact: Deborah Gibbs, COMT; 404-778-5815
Sponsor: Ophthotech
Posted: 04-23-2014
A Prospective, Multicenter Post-Approval Study of VisionCare's Implantable Miniature Telescope in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration
PI: Joung Kim, MD
Coordinator: Jayne Brown
Status: Enrolling
General Summary: The purpose of the IMT PAS 01 is to evaluate the safety of the intraocular telescope for the treatment of bilateral end-stage age-related macular degeneration following U.S. market approval
Clinical Summary: Patients will be closely followed for 5 years post implantation. Clinical parameters for both eyes: slit lamp & fundus exams, BCVA, IOP and corneal endothelial cell density measurement.
Inclusion Criteria:
- Retinal findings of geographic atrophy or disciform scar
- Evidence of significant cataract
- Achieve 5 letter improvement with an external telescope
- Agree to participate in post op visual training
- Minimum age of 65 years
Exclusion Criteria:
- Stargardt's macular dystrophy
- Corneal guttata
- Must meet endothelial cell density requirements per protocol
Contact: Jayne Brown, Clinical Research Coordinator,
Date Posted: 02-02-2012;
Updated: 11-03-2014; 04-27-2016
DRCR: Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
PI: Jiong Yan, MD
Coordinator: Judy Brower, COMT
Status: Enrollment Closed
General Summary: Standard treatment for Proliferative Diabetic Retinopathy (PDR) is laser. This study is to determine whether injections of a drug into the eye can treat PDR as well as laser treatment but with fewer side effects. Half of those enrolled will receive laser immediately, the other half will receive monthly injections as long as needed or until it is determined that laser is needed. Eyes that receive injections will have visits monthly as long as injections are needed. Eyes that received prompt laser will be seen every 16 weeks, unless needed to be seen more often. Follow-up will be 5 years - Years 4 and 5 are yearly visits only.
Inclusion Criteria:
- At least 18 years of age
- Type I or II diabetes mellitus
- Proliferative Diabetic Retinopathy
Exclusion Criteria:
– History of previous PRP laser
– Any condition affecting visual acutiy other than PDR
– History of eye injection (anti-VEGF) in the past 2 months.
– History of corticosteroid treatment in the past 4 months
– Major ocular surgery in past 4 months or expected in next 6 months
– History of YAG laser in past 2 months
Contact: Judy Brower, COMT,
Posted/Updated: 07-24-2012; 01-18-2013
DRCR: Genes in Diabetic Retinopathy Project
PI: Jiong Yan, MD
Coordinator: Linda Curtis
Status: currently enrolling
General Summary: The purpose of this study is to collect blood and DNA from diabetics for scientists to study. These samples will be stored at a Research Bank in Seattle, Washington. Information about the samples will be stored in Tampa, Florida.
Scientists may request some samples for their research on diabetes, complications from diabetes, such as diabetic retinopathy or other diseases. The DRCRnetwork will need to approve the request before the samples will be given to the scientists. One or two tubes of blood will be drawn. The information collected may be updated with information about eye exams, diabetes, other medical conditions, and treatments. There will be at least 2000 people in this study.
Inclusion Criteria: Currently or previously enrolled in one of the applicable DRCR.net studies
Exclusion Criteria:
Contact: Linda Curtis, 404-778-4261
Date Posted: 07-24-2012; 07082013
MacTel - A Phase 2 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotropic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel) - Protocol NTMT-02
PI: Jiong Yan, M.D.
Coordinator: Donna Leef, MMSc, COMT
Status: recruitment closed, follow-up phase
General Summary:
MacTel is a disorder of the blood vessels which supply the macula, the central part of the retina that lines the back of the eye and picks up the light like the film in a camera. The "fovea," in the center of the macula, has no blood vessels at all because they would interfere with central vision. MacTel refers to a curious, very poorly understood condition of the blood vessels around the fovea (juxtafoveal) which become dilated and incompetent, like varicose veins but on a much smaller scale.
While MacTel does not usually cause total blindness, it commonly causes loss of the central vision, which is required for reading and driving vision, over a period of 10-20 years. There is no current approved treatment for MacTel. This study will evaluate whether an experimental implant containing Ciliary Neurotrophic Factor (CNTF) can be used to treat people with MacTel. CNTF is a small molecule that may help keep some nerve cells in the eye healthy. The implant, called NT-501, is a small capsule of cells that is placed inside the eye to allow the release of CNTF directly to the retina, the light sensitive part of the eye.
Clinical Summary:
This study will have two equal groups:
(A) NT-501 implant: the surgical implantation of the NT-501 implant
(B) Sham procedure: the placement of a dissolvable suture on the eye. A Sham procedure does not involve any treatment. It is like a control or placebo group
Inclusion Criteria:
Some of the inclusion criteria include:
• Age 21 to 79
• Must have at least one study eye with a diagnosis of MacTel Type 2 with evidence of fluorescein leakage typical of MacTel or at least one of the other features including retinal opacification, crystalline deposits, right angle vessels, inner/outer lamellar cavities or hyperpigmentation not involving the center of the fovea, but no evidence of intraretinal/subretinal neovascularization
• Vision 20/50 or better
• After study testing and measurements at the screening visit, study eligibility requirements are met and confirmed by an independent reading center
Exclusion Criteria:
• Received intravitreal therapy for non-neovascular MacTel within the last 3 months (steroids) and within the last month (anti-VEGF)
• Is pregnant or breastfeeding
• Has a history of malignancy that would compromise the 24-month study survival
• Is on immunosuppressive therapy
• Is considered immunodeficient or has a known history of HIV;
• A history of ocular Herpes virus
Contact: Donna Leef, MMSc, COMT, (404) 778-4134, email@example.com
Posted: 05/13/2015
A Compassionate Use of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor for Participants with Retinal Degenerative Diseases
PI: Jiong Yan, M.D.
Coordinator: Donna Leef, MMSc, COMT
Status: follow up
General Summary:
This study is to collect extended data on patients who were previously implanted with a capsule which releases a substance called "CNTF" into the fluid of ther eye. CNTF is a naturally occurring substance in the body that acts to protect nerve cells. The CNTF implants were developed by Neurotech Pharmaceuticals USA, the sponsor of this trial. All of the enrolled 9 participants have had the capsule implanted for more than 24 months.
Clinical Summary:
To further evaluate participant safety and to continue collecting information on the effectiveness of the implant, we are asking those patients who were originally implanted to continue participating in this study for one additional "extension" study visit. The additional study visit will take place between Month 26 and 50 after the date of the implant.
Inclusion Criteria: Previous participant in the Compassionate Use of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor for Participants with Retinal Degenerative Diseases between 2011 and 2012.
Exclusion Criteria:
Not a participant in the Compassionate Use of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor for Participants with Retinal Degenerative Diseases between 2011 and 2012
Contact: Donna Leef, MMSc, COMT (404) 778-4134, email@example.com
Posted: 05/14/2015
Argus II Retinal Prosthesis System Post Approval Study (Protocol PM-02-01)
PI: Jiong Yan, MD
Coordinator: Jayne Brown
Status: Active
General Summary: The purpose of this study is to collect additional information from Argus II users in order to monitor the system's safety and collect additional data about how much it improves people's visual function and activities of daily living.
Clinical Summary: This study is a 5 year post-market approval study, to collect additional information regarding safety and performance of the ARGUS II. The ARGUS II is approved as a Humanitarian Use Device.
Inclusion Criteria:
- at least 25 years old
- severe to profound retinitis pigmentosa diagnosis
- previous history of useful form vision
- bare or no light perception in both eyes
Exclusion Criteria:
- ocular structures or conditions preventing successful working of or implantation of the device
- inability to tolerate general anesthesia, or antibiotic and steroid regimen
- pregnancy or plans to become pregnant during course of study
Contact: Jayne Brown, 404-778-4430 office phone
Posted: 01-02-14
CLS1001-301 (PEACHTREE): A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema associated with Non-Infectious Uveitis
Steven Yeh, MD
Coordinator: Jayne Brown
Status: Enrolling
General Summary:
This is a phase 3, randomized, sham controlled, multi-centered study to evaluate the safety and efficacy of 4 mg suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.
Clinical Summary:
The study design includes a maximum of 8 clinic visits over a maximum of 27 weeks. Qualified subjects will be randomized to receive 2 unilateral suprachoroidal injections of CLS-TA to the study eye or 2 unilateral sham injection procedures approximately 12 weeks apart. Local medications for fellow eye are allowed. Rescue criteria is determined by protocol guidelines with treatment determination at Investigator's discretion.
Inclusion Criteria:
1. Non-infectious uveitis of any etiology and from among those with anterior, intermediate, posterior and pan uveitis.
2. Macular edema greater than 300 microns determined by OCT.
3. BCVA between 20/70 and 20/800 Snellan equivalent.
4. 18 yrs or older.
Exclusion Criteria:
1. Significant media opacity.
2. IOP greater than 22 mmHg (can be on 2 IOP lowering medications) or uncontrolled glaucoma.
3. History of vitreoretinal surgery within 3 months prior to Visit 2.
4. High myopia (greater than 26mm axial length).
5. Photocoagulation or cryotherapy 6 months prior to Visit 2.
6. Intravitreal injection of anti-VEGF treatment within 30 days.
7. Topical ocular corticosteroid within 10 days, intraocular and periocular corticosteroid injection within 2 months, OZURDEX implant within 6 months, RETISERT or ILUVIEN insert within 3 years of Visit 2.
8. Systemic steroids greater than 20 mg per day within 2 weeks of Visit 2. Subjects on stable dose of less than 20 mg per day with no anticipated dose increase during study can be enrolled.
Contact: Jayne Brown, (404) 778-4430
Date Posted: 04-18-2016
PeriOcular and INTravitreal corticosteroids for uveitic macular edema (POINT)
Trial PI: Steven Yeh, MD, Associate Professor of Ophthalmology Coordinator: Alcides Fernandes Filho, MD
Status: Recruiting
General Summary: Macular edema is the most common complication and leading cause of visual loss in patients with uveitis. Approximately 40% of patients with intermediate uveitis, posterior uveitis, or panuveitis develop macular edema. Ocular injections of corticosteroids are the most frequently used treatments specifically for uveitic macular edema but there is a lack of high quality evidence to guide choice of drug (e.g., triamcinolone acetonide, dexamethasone) and route of administration (e.g. periocular, intravitreal). The question of how to approach local treatment of uveitic macular edema is a key question for ophthalmologists treating these patients.
The Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial is a randomized trial designed to compare the relative efficacy of three regional corticosteroids commonly utilized for the initial regional treatment of uveitic macular edema, periocular triamcinolone, intravitreal triamcinolone, and the intravitreal dexamethasone implant.
The design outcome is the percent change in central subfield macular thickness on OCT from baseline to the 8 week visit. Follow-up through 24 weeks will allow evaluation of the duration of response and the need for additional injections. Secondary outcomes include resolution of macular edema, IOP elevation, visual acuity, complications of treatment, and cost-effectiveness.
Clinical Summary: The POINT Trial was designed to evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant.
After signing informed consent and undergoing eligibility evaluation, eligible patients will be randomized to one of the three study treatments to be administered at the first study visit. Randomization is by participant, if both eyes meet eligibility requirements then both eyes receive assigned treatment. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks.
After assessment of the primary outcome at 8 weeks, second injections and best medical judgment will be used if macular edema has not improved as follows:
Eye(s) meeting trial eligibility criteria receive initial injection of assigned treatment at P01 visit.
Second injection of assigned treatment permitted at 8 week visit for periocular triamcinolone and intravitreal triamcinolone and at 12 week visit for intravitreal dexamethasone if
- Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) or
- Eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield or
- ME is worse after initial improvement And the following repeat injection criteria are met:
- IOP of ≤21 or mm Hg and treatment with ≤2 IOP-lowering agents;
- Best corrected visual acuity of 20/40 or worse;
Eyes demonstrating no improvement or worsening of ME as measured by the central submacular thickness on OCT (at week 12 for periocular and intravitreal triamcinolone arms and at week 20 for intravitreal dexamethasone arm) are considered primary treatment non-responders.
Inclusion Criteria:
1. 18 years of age or older;
Eye level inclusion criteria - at least one eye must meet all of the following conditions:
2. Non-infectious anterior, intermediate, posterior or panuveitis; either active or inactive uveitis is acceptable;
3. Macular edema (ME) defined as the presence of central subfield macular thickness greater than the normal range for the OCT machine being used, regardless of the presence of cysts, as assessed by study ophthalmologist;
4. Best corrected visual acuity (BCVA) worse than 20/32 and 5/200 or better;
5. Baseline intraocular pressure > 5 mm Hg and ≤ 21 mm Hg (current use of 2 or fewer intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable);
6. Baseline fluorescein angiogram that is gradable for degree of leakage in the central subfield
7. Pupillary dilation sufficient to allow OCT testing.
Exclusion Criteria:
1. History of infectious endophthalmitis or infectious uveitis in either eye;
2. History of scleritis or keratitis of any type in either eye;
3. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial;
4. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;
5. Oral prednisone dose > 10 mg per day (or of an alternative corticosteroid at a dose higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10 mg per day that has not been stable for at least 4 weeks;
6. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks;
7. Known allergy or hypersensitivity to any component of the study drugs;
Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot have any of the following conditions:
8. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9 or any notching of optic nerve to the rim);
9. Media opacity causing inability to assess fundus or perform OCT;
10. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of study ophthalmologist may be significant enough to limit improvement of ME (i.e., causing substantial wrinkling of the retinal surface) 81;
11. Presence of silicone oil;
12. Periocular or intravitreal corticosteroid injection in past 8 weeks;
13. Injection of dexamethasone intravitreal implant in past 12 weeks;
14. Placement of fluocinolone acetonide implant (Retisert) in past 3 years;
15. Topical NSAID use if dose has not been stable for at least 4 weeks.
Contact: Alcides Fernandes Filho, (404) 778-2421,
Date Posted: 11-3-2015
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis: The EYEGUARD™, A Study
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Closed to enrollment
General Summary: The purpose of this study is to find out more about how gevokizumab works, and if it has an effect on eye condition by limiting the action of IL-1β, one of the proteins in the body that causes inflammation. Patients will be followed through Visit Day 448 and will have the option to roll into an open label study if necessary.
Clinical Summary: The primary objective of this study is to demonstrate the superiority of gevokizumab (at least one of the two doses) compared to placebo in the treatment of subjects with active non-infectious intermediate, posterior, or pan- uveitis. In addition, the safety of gevokizumab will be assessed.
Inclusion Criteria:
-active non-infectious intermediate, posterior or pan uveitis indicated by 2+ vitreous haze in one eye
-on current stable treatment regimen
Exclusion Criteria:
-history or symptoms of demyelinating disease
-seropositivity for HIV, Hepatitis B or C
-advanced glaucoma, or on >3 IOP lowering medications
Contact: Jayne Brown, 404-778-4430
Date Posted: 05-08-2014
Last Updated: 04-27-2016
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment: The EYEGUARD™-C study
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Closed to enrollment.
General Summary: The purpose of this study is to find out more about how gevokizumab works, and if it has an effect on eye condition by limiting the action of IL-1β, one of the proteins in the body that causes inflammation. Patients will be followed through Visit Day 448 and will have the option to roll into an open label study if necessary.
Clinical Summary: The primary objective of this study is to demonstrate the superiority of gevokizumab (at least one of the two doses) compared to placebo in reducing the risk of recurrent uveitic disease in subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment. In addition, the safety of gevokizumab will be assessed.
Inclusion Criteria:
-history of active uveitis disease in either eye within 12 months
-controlled uveitis with <0.5 vitreous haze in both eyes
-on stable dose of corticosteroids > 10mg/day
Exclusion Criteria:
-advanced glaucoma or on >3 IOP lowering medications
-seropositivity for HIV or Hepatitis B or C
-history or symptoms of demyelinating disease
Contact: Jayne Brown, 404-778-4430
Date Posted: 05-08-2014
Last Updated: 04-27-2016
A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-Infectious Anterior Segment Uveitis
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Open to enrollment
General Summary: The purpose of this study is to see how well a new drug and associated drug delivery system treat patients with non-infectious anterior uveitis compared to Prednisolone Acetate (positive-control eye drops), the standard of care.The study drug, Dexamethasone Phosphate, and associated drug delivery system, ocular iontophoresis are investigational, which means they have not yet been approved by the United States Food and Drug Administration (FDA).
Clinical Summary: This is a prospective, multi-center, randomized, double-masked, Phase 3 clinical trial designed to evaluate the efficacy and safety of ocular iontophoretic delivery of dexamethasone phosphate ophthalmic sloution to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Inclusion Criteria: Adults diagnosed with non-infectious anterior segment uveitis defined as an anterior chamber cell count greater than or equal to 11 cells.
Exclusion Criteria:
- Have intermediate or posterior uveitis.
- Have used topical corticosteriod in the study eye less that 48 hours prior to Baseline Visit.
- Have used oral corticosteroid within 14 days of Baseline Visit.
- Steroid responder in either eye.
Contact: Jayne Brown, Clinical Research Coordinator, 404-778-4430
Sponsor: Eyegate Pharmaceuticals
Date Posted: 07-25-2012
Last Updated: 04-27-2016
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Closed to enrollment
General Summary: All patients will receive open label adalimumab regardless of their previous treatment assignment in the randomized, double masked studies. Maximum duration of this study is 78 weeks.
Clinical Summary: Patients who discontinue from M10-880 and M10-877 will receive adalimumab 40 mg eow SC. Concomitant oral or topical corticosteroids and any one of the allowed immunosuppressive therapies permitted in the previous trial will be allowed as necessary to control ocular inflammation in patients with active disease. Patients are followed very closely with clinical examinations and laboratory testing.
Inclusion Criteria:
-patients previously enrolled in either M10-880 or M10-877 who have discontinued or completed these protocols.
Exclusion Criteria:
-IOP greater than 25mmHg and on 2 glaucoma medications
-isolated anterior uveitis
Contact: Steven Yeh, MD at 404-778-5070 or Jayne
Brown 404-778-4430
Sponsor: Abbott Laboratories
Date Posted: 05-25-2011
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Closed to enrollment
General Summary: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate, Posterior or Panuveitis.
Clinical Summary: The objective of this study is to evaluate efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week subcutaneously staring at Week 1 compared to placebo as maintenance therapy in patients requiring high dose corticosteroids for active uveitis.
Inclusion Criteria:
- patients with active disease despite 2 weeks maintenance therapy of greater than 10 mg prednisone
- prior adequate response to oral corticosteroids
- negative TB screening
Exclusion Criteria:
- isolated anterior uveitis
- IOP greater than 25 mmHg and on 2 glaucoma medications
- previous exposure to anti-TNF therapy
Contact: Steven Yeh, MD at 404-7785070 or Jayne Brown at 404-778-4430
Sponsor: Abbott Laboratories
Date Posted: 04-19-2011
PI: Steven Yeh, MD
Coordinator: Jayne Brown
Status: Closed to enrollment
General Summary: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis.
Clinical Summary: This is a phase 3, randomized, double masked, placebo-controlled, multi-centered study to investigate the efficacy and safety of adalimumab in uveitis subjects who are unable to taper cortiosteroids without experiencing a flare.
Inclusion Criteria:
- noninfectious, intermediate, posterior or panuveitis
- AC cell grade and haze less than 0.5+
- history of having failed corticosteroid taper within 18 months
- corneal or lens opacity that precludes fundus visualization
- isolated anterior uveitis
- less than 20/200 in one eye
Contact: Steven Yeh, MD at 404-778-5070, or Jayne Brown at 404-778-4430
Date Posted: 11-29-2010
Last Updated: 01-13-2015
A 24 week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression in patients with quiescent, non-infectious, intermediate, posterior, or panuveitis (ENDURE and 38 week ENDURE Extension study).
PI: Steven Yeh, MD
Coordinator: Jayne M. Brown
Status: Closed to enrollment
General Summary: This study will find out if AIN457 along with standard treatment could suppress and prevent and active uveitis recurrence as compared to standard treatment alone.
Clinical Summary: Patients will be randomized to AIN457 versus placebo and receive subcutaneous injections during a 24 week treatment period. Patients are followed with clinic examinations every other week for 24 weeks.
Inclusion Criteria:
- less than grade 1, AC cell and vitreous haze
- no increase in immmunosuppressive medications within 6 wks
- patients willing to be weaned from current systemic therapy
- at least 18 years old
Exclusion Criteria:
- patients requiring greater that 1 mg/kg daily of cortocosteroids to maintain quiescence
- infectious uveitis
- active uveitis with AC cell or vitreous haze greater than grade 1
- pregnancy
- intravitreal anti-VEGF agents within 3 months
Contact: Jayne M. Brown, 404-778-4430
AIN457 An open-label, proof-of-concept study with a double-masked, dose ranging component to access the effects of AIN457 in patients with non-infectious uveitis
PI: Steven
Yeh, MD
Coordinator: Jayne M. Brown
Status: Closed to enrollment
Summary: This trial examines the study drug AIN457, given by infusion, to see if it is safe and has beneficial effects for patients with non-infectious uveitis.
Patients 18 -75 years with non-infectious uveitis requiring systemic immunosupression. Screening vitreous haze and anterior chamber cell scores must be +1 or worse.
Exclusion criteria:
Systemic disease that would contraindicate long-term immunosupression, especially infectious diseases that can spontaneously re-emerge such as tuberculosis; white blood cell or platelet count below normal; abnormal EKG; ocular surgery within 6 months; laser in study eye within 3 months.
Contact: Jayne
M. Brown, 404-778-4430
Sponsor: Novartis Pharmaceuticals
Last Updated: 07-24-2012
Multicenter Uveitis Steroid Treatment (MUST) Trial
PI: Steven Yeh, MD
Coordinator: Alcides Fernandes, MD
Status: Closed to enrollment
Summary: This research was designed to determine if a new FDA approved treatment is safer and more effective than the standard treatment for certain types of uveitis. The two treatment arms of this study are a corticosteroid implant (the new FDA approved treatment, Retisert® implant) and oral corticosteroids (the standard FDA approved treatment). Both treatments are known to be effective for treating uveitis. Neither treatment is experimental.
- Patients with active intermediate, posterior, or pan-uveitis
- 13 years or older
- Best corrected VA of hand motion or better
- Baseline Intraocular pressure of 24mm Hg or less
- Patients with Diabetes Mellitus
- Allergy to steroids
- Uncontrolled glaucoma or advanced glaucomatous optic nerve damage
- Immunocompromised patients
- Pregnant or currently breast-feeding patients
Contact: Alcides
Fernandes, MD, 404-778-2421
Sponsor: NEI, NIH
Copyright © Emory Eye Center - All Rights Reserved | Emory Clinic Building B, 1365B Clifton Road, NE, Atlanta, Georgia 30322 USA


text:
Welcome to PGD
If this is your first visit, be sure to check out the FAQ by clicking the link above. You have to register before you can post.
If you have recently signed up, please make sure you log in so that your activity is registered. This is required for automatic promotions to work and to ensure your account is not deleted during the registration process.
I had to create this thread a lot of time ago. My fault.
In my new job we created a small game studio, and I'm near to finish the first
I just wrote a massive post all about progress, features, requests for like-minded individuals to join me and an internet error caused it all to be lost
Hi there,
I've been working non-stop on a project and have burned myself out... quite literally... and now I am having a problem that I no


text:
BattlefieldShared publicly -
Battlefield 4 Legacy Operations will include Air Superiority option for RSPs. Will you be hopping in a Jet or a Heli?
Add a comment...
180 comments
With more than 65 million players worldwide, DICE's Battlefield series is the premier tactical shooter. Whether it's the classic Battlefield 1942, the irreverent Battlefield: Bad Company, the groundbreaking Battlefield 3 or the upcoming Battlefield 4 taking the series into a new era, Battlefield delivers best in class online vehicle warfare. Join us on the Battlefield.


text:
Handling an officer after an officer-involved shooting
By Dave Smith and Betsy Brantner-Smith
If you need further help setting your homepage, check your browser's Help menu
By Dave Smith and Betsy Brantner-Smith
Login Problems? If you have any problems with registration or login, or if you would like to inquire about your secure confirmation, please do not hesitate to contact us online. Please check out our FAQ page.


text:
The Voice of the PEI Tourism Industry
Nominate an Industry Member!
The Tourism Industry Association of PEI is now accepting nominations for the Annual Industry Awards which will be presented in March in conjunction with the TIAPEI Tourism Conference & Awards Gala. Nominations for awards can be made on behalf of individuals, businesses, and organizations representing excellence in the tourism industry.
For more information, or to make a nomination, please visit our website.
RFP Google Analytics workshop development and delivery
As a project partner, TIAPEI is requesting proposals for the development and delivery of a one-day workshop focused on Google Analytics.
2021 Tourism Strategy
Visit the Tourism Matters 2021 Strategy page for more information about how you can get involved!
TIAPEI Lunch & Learn Schedule
Join TIAPEI in our New Lunch and Learn series! These quick seminars will be every Thursday from noon-1pm and will feature different topics each time. This is also a great way to get out and meet other members and learn some new information, all at the same time.
TIAPEI 2016 Event Calendar
TIAPEI has outlined the entire 2016 event calendar. Click for more information.
Latest Tourism Numbers
The 2015 tourism indicators are available. Review them here. Tourism Operators can always find the most current tourism numbers on our website.
Get the latest Tourism Stats for PEI
TIAPEI is committed to providing our industry with the most up-to-date information. Get the latest tourism statistics here.
TIAPEI Membership
Membership is open to all tourism operators, as well as any individual or company interested in the industry and the particular objectives ...
TIAPEI Partners and Supporters for 2016
Follow us on Twitter
Add @TIAPEI to your Twitter account twitter.com/tiapei
TIAPEI on Facebook
Like us on Facebook facebook.com/tiapei


text:
Lucrative Data Entry Project
This project received 20 bids from talented freelancers with an average bid price of €5035 EUR.Get free quotes for a project like this
Skills Required
Project Budgetmin €5000 EUR
Total Bids20
Project Description
Dear Freelancer
Our customer is a software house who will launch new billing software worldwide.
Your jobs will be a very easy Data Entry activity.
You have to find and up load utility bill and fill our description form (2 minutes).
As utility bill we accept Gas, Water, Electricity, Cable TV, Landline Phone bill, Broadband (internet).
Once we have approved the kind of document that you want to send us you can fill the form on line
This jobs is already finished for this nations
Sri Lanka
We don't accept more utility bills for these nations.
You will be paid weekly on Tuesday by PayPal or Moneybookers
We offer a very good payment. You will receive:
US $ [url removed, login to view] for every utility bill scanned/photographed or
US $ [url removed, login to view] for every utility bill in digital format.
An extra US $ [url removed, login to view] for every utility bill from European countries
For any questions, send us a message.
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Login/Create Account
Check Out the new Remax App
Ask About This Home
Custom parade home by American Dream Homebuilders. Very well acquainted with over 3000 square feet. 6 bedrooms and 3 bath that is fully finished. Open floor plan with beautiful finishes including tile granite counter tops, tile floors, kitchen island, and gas fireplace. Main floor master bedroom and master bath suite with double vanities and jetted tub. Fenced yard with no neighbors in the back and RV parking. Sprinkler system. Central air. Triple car garage.


text: Dr. Michael Grace On Inside Florida Tech By Wes Sumner • Apr 3, 2013 ShareTwitter Facebook Google+ Email Listen Listening... / 4:21 On this edition of Inside Florida Tech host Wes Sumner interviews Associate Dean of the College of Science, Dr. Michael Grace. Dr. Grace talks about the upcoming 2013 Northrop Grumman Engineering and Science Student Showcase. Related Program: Inside Florida TechTags: Inside Florida TechView the discussion thread.


text:
In ye olden days - oh, until about seven years ago - the Broad Axe Tavern turned out pricey, traditional fare at Butler and Skippack Pikes in Whitpain Township, while regular folks went next door to the casual mainstay Phil's Tavern for sandwiches and heaping portions of all-American fare.
As of this week, there's a new choice in the Blue Bell/Ambler/ Gwynedd corridor as the Broad Axe Tavern (901 W. Butler Pike, 215-643-6300) has reopened after a renovation that took the circa-1681 landmark down to three stone walls and aimed the culinary approach in a more everyday direction.
Managing partner Matt Doman, former chef at the William Penn Inn, oversees a warmly decorated operation with a bar and assorted dining rooms on two floors (one looks into an open kitchen) and a meeting/banquet room on the third. It's also "green," with an oil-recycling system and takeout containers made from recycled material.


text:
I was recently privileged to be given the opportunity to ask Denise Bahs, social media coach with Profitecture and payment specialist, a few questions about the role that social media is currently paying in the payments industry and what it's role may be in the future.
1. American Express has recently added Twitter to its Amex Sync program. Amex Sync allows card holders to securely connect their cards to social networks to take advantage of special offers. How do you think the users of these social networks will respond? Do you think people are ready to trust the social networks enough to connect their credit cards to them?
I've used this service in order to "road test" it. It went smoothly; however, my peers (Gen X) are not likely to adopt this yet. Based on an informal poll I conducted of my "friends" they do not trust social networks with their banking information. Count me in on that boat. However, I think Gen Y and the Millennials will have no problem adopting it. They live in that space and will bank there too. As long as there is a value proposition, I think they will embrace it.
2. Do you see more merchants getting on board and trying to take advantage of the opportunities that a program like Amex Sync provides?
If merchants are smart they will figure out a way to entice consumers into paying with their phones (inside the social channels and out). Paying with a smartphone in concert with big data on shopping habits, purchasing time of day and show rooming…put it all together and you've got some powerful buying predictors.
3. How connected can the social media networks and payment industry become? Will we one day be shopping for new shoes on Facebook and sharing the entire experience with our followers?
I wrote a blog post about this. Facebook should be careful. When I can stand on the backs of my friends to get a good discount, they will begin to question how great of friends we are. I also question the following moral question that this implies: is my value as a human being only as large as my social network? Will I get a bigger discount if I have a bigger network? That's ugly.
4. Do you feel that it's important for every merchant to be active on social media in an attempt to connect with their customers?
Not every social channel is right for every merchant. They need to figure out where their customers are and be there.
5. Are the social networks a good tool for merchants to use to get to know their customers?
People who really "get" social media understand that in order to benefit from it, you have to listen. That is especially true for merchants. If all they are doing is broadcasting sales messages to their followers, they will find they don't have many followers left. It's about listening and engaging.
6. Lastly – Congratulations to you and your team over at VerifyValid for being a finalist in the Best Check Innovation Category from Pymnts.com. That must have been a very exciting time.
Thank you! Yes, it was very exciting and we are still reaping the rewards of trying to win! See my blog post, Innovation Project 2013, Reward not Award.
Denise Bahs, AAP is a social media coach with Profitecture, blogger, payments specialist and is particularly interested in the differences between the generations. What makes people tick and how has social media changed banking and payments? With nearly 20 years in the banking and payments/marketing industry, she is uniquely positioned where those two areas converge: social and banking. To read more, visit her blog at www.denisebahs.com/blog.


text:
Best route map between Middlesboro, KY and Sevierville, TN. This route take about 84 Miles.
The distance and estimated time is placed on the right depending on the status of the road.
, 01:00
* You can see Middlesboro, KY and Sevierville, TN photos above. We provide this photos from Google Panoramio service.
* Middlesboro, KY weather as celsius: °C
* Sevierville, TN weather as celsius: °C
* Weather information on route, provide by Open Weather Map.
All Rights Reserved. © 2010 - 2016 About Feedback


text:
How Do You Like Georgia May Jagger As a Chanel Girl?
Karl Lagerfeld shot her for the new resort look book.By Amy Odell
Karl Lagerfeld shot her for the new resort look book.By Amy Odell
The motorcycle used in the finale broke down on the runway.By Amy Odell
Also, Armani will open in airports, and don't miss Bruno Pieters's new ad campaign.
You know, for school.By Amy Odell
And Chanel Iman's mother opened her own clothing store.
Also, Georgia May Jagger says she is not the next Ultimo girl.By Sharon Clott
Also, Veronique Branquinho is designing again.By Sharon Clott
Also: drug rumors.By Amy Odell
And the Target collections by Sonia Kashuk and Rodarte share the same animal-print fabric.By Sharon Clott
And more highlights!By Amy Odell
Also, Catherine McNeil is back and on the cover of Australian 'Vogue.'By Sharon Clott
And preview Georgia May Jagger's campaign for Rimmel London.By Sharon Clott
And Japanese swimmers can't show their beauty flare.By Sharon Clott
And M.A.C. Cosmetics teamed up with Lilly Pulitzer to launch a collection.By Sharon Clott
Five new stores, from Soho to the Upper East Side.By Lauren Murrow


text:
Pokemon X
This is a split board - You can return to the Split List for other boards.
How do you know if your GameStop is doing a midnight release?
- Topic Archived
Report Message
Terms of Use Violations:
Etiquette Issues:
Add user to Ignore List after reporting
Topic Sticky
- Topic Archived